November batch of EMA/CHMP recommendations

As a result of its November 8-11 meetings, the European Medicines Agency’s human medicines committee, the CHMP, today announced a number of drug approval recommendations. A final decision will come from the European Commission, which usually takes around two to three months.

Among these are the following:

Switzerland’s Vifor Pharma Group’s (SWX: VIFN) Tavneos (avacopan) was granted a positive opinion for the treatment of adult patients with severe, active granulomatosis with polyangiitis or microscopic polyangiitis, a rare type of inflammation of the blood vessels.